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Background: The prevalence of multidisciplinary teams (MDT) for the delivery of cancer care is increasing globally.
Evidence exists of benefits to patients and healthcare professionals. However, MDT working is time and resource
intensive. This study aims to explore members’ views on existing practices of urology MDT working, and to identify
potential interventions for improving the efficiency and productivity of the MDT meeting.
Methods: Members of urology MDTs across the UK were purposively recruited to participate in an online survey.
Survey items included questions about the utility and efficiency of MDT meetings, and strategies for improving the
efficiency of MDT meetings: treating cases by protocol, prioritising cases, and splitting the MDT into subspeciality
meetings.
Results: 173 MDT members participated (Oncologists n = 77, Cancer Nurses n = 54, Urologists n = 30, other
specialities n = 12). 68% of respondents reported that attending the MDT meeting improves efficiency in care
through improved clinical decisions, planning investigations, helping when discussing plans with patients, speciality
referrals, documentation/patient records. Participants agreed that some cases including low risk, non-muscle invasive
bladder cancer and localised, low-grade prostate cancer could be managed by pre-agreed pathways, without full MDT
review. There was a consensus that cases at the MDT meeting could be prioritised by complexity, tumour type, or the
availability of MDT members. Splitting the MDT meeting was unpopular: potential disadvantages included loss of
efficiency, loss of team approach, unavailability of members and increased administrative work.
Conclusion: Key urology MDT members find the MDT meeting useful. Improvements in efficiency and effectiveness
may be possible by prioritising cases or managing some low-risk cases according to previously agreed protocols.
Further research is needed to test the effectiveness of such strategies on MDT meetings, cancer care pathways
and patient outcomes in clinical practice.
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Evidence is emerging of the benefits of multidisciplinary
working in cancer care [1]. In the UK multidisciplinary
team (MDT) working in cancer care has been mandatory
for over a decade, and all cases of new or suspected cancer
must be discussed in an MDT meeting [2]. Such teams,
which involve surgeons, radiation and medical oncologists,
radiologists, pathologists, sometimes specialist nurses* Correspondence: Benjamin.lamb@imperial.ac.uk
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unless otherwise stated.(always in the UK) and MDT coordinators, work together
and meet regularly (e.g. weekly) to plan investigations and
treatment for patients [2].
The concept of MDT-driven care in cancer is recognised
internationally, however, its uptake varies. MDT-driven
care is more firmly embedded into some healthcare
systems (e.g. UK, Australia) than others (e.g. US) –
possibly due to a combination of differences in the
geography of healthcare institutions (e.g. centralised
care approach, driven by cancer centres in the UK ver-
sus largely community-based care delivery in the US),
financial drivers, and potentially also the nature of thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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emerged indicating benefits of MDT driven care –
overall however the evidence is not conclusive or based
on strong research designs. Reviews indicate that over-
all MDTs do improve the care process, and the largest
study that we are aware of to date on breast cancer pa-
tients also indicates improved survival [1,3,4].
Recent thinking on MDTs has focused on how the
teams actually function and how MDT meetings run in
practice. Consensus over what constitutes effective MDT
working is high, and MDT members remain positive
about MDTs [5,6]. It is thought that time spent at the
MDT saves time for members later [7-9]. A key problem
in MDT working in settings with high patient volumes
is that team meetings are often fast-paced, with large
numbers of cases leaving inadequate time for in-depth
discussion [10-12]. In addition to the initial MDT dis-
cussion of cases of newly diagnosed cancer, many cases
will need repeated discussion at the MDT meeting at
various points along the care pathway – e.g. when plan-
ning or reviewing the results of treatment. Moreover,
although there is no obligation to discuss cases of recur-
rent or relapsing disease, such cases are often complex
and thus may benefit most from a MDT approach [13].
With increasing numbers of cancer patients being man-
aged by MDTs, one critique of the current MDT process
is that it is time and resource intensive – such that the
team-members in attendance do not have adequate time
to prepare for the meeting [14]. Further, how best to
represent the patient’s interests and views within the
meeting remains an area of debate: there is agreement
that MDT treatment plan should be explained and fully
discussed with patients afterwards, however, most mem-
bers do not support the inclusion of patients in MDT
meetings, arguing that this will increase their anxiety
and potentially hinder the case review [14-16].
To address some of the issues above, there is an in-
creasing body of research aiming to evaluate how MDTs
function and what the quality of their decision making is
[3,4]. Ultimately, such descriptive studies aim to provide
a background for the improvement of MDT working
and clinical decision-making in order to ensure that
every case receives thorough and comprehensive review
[3,4,17]. Meeting efficiency features highly in the emer-
ging evidence – in other words, there is increasing inter-
est in how the efficiency of MDT meetings can be
improved to allow in depth discussion of cases that re-
quire complex decision-making, avoiding inappropriate
use of time or resources on simple cases, whilst ensuring
that quality assurance is guaranteed for all cases. Pro-
posed solutions include treating simple cases by protocol
and approving such treatment plans outside the MDT
meeting; prioritisation of cases; and splitting larger, high-
volume MDTs into smaller, more specialist and hencemore manageable meetings (i.e. individual MDT meetings
for prostate, bladder and kidney cancers, instead of a very
large ‘urology’ MDT).
This study aims to better understand MDT working
and add to the relevant evidence – with a specific focus
on the urology MDT. The specific objectives of this
study were to assess the perceptions of MDT members
regarding:
 The usefulness of MDT meetings
 Whether MDT working saves time later, and if
so, how
 Strategies for improving the efficiency of MDT
meetings, namely
 Treating some cases by pre-defined protocol,
with ratification of management plans by the
MDT chair alone
 Prioritising cases at the MDT meeting
 Splitting large MDT meetings into smaller,
subspeciality ones




Two surveys were conducted on separate occasions.
The first survey was sent to the attendees of the British
Uro-oncology Group (BUG) annual meeting in 2011.
The second survey was administered to the attendees of
a national Royal Society of Medicine (RSM) meeting that
was jointly organised by the Oncology Section of the
RSM and BUG in 2012 (‘What’s new – What’s changing
in prostate cancer?’ meeting). Recruitment was purposive
in order to ensure representation of key members of the
urology MDT, i.e. professional groups who have direct
clinical contact with patients: Urological Surgeons, Cancer
Nurse Specialists (CNS), and Uro-Oncologists. The survey
link was emailed to the attendees of the events prior to
the meetings. No reminders were administered, as this
was not feasible.
Study design and materials
This was a prospective cross-sectional study. MDT
members were sent an electronic invitation to fill out an
electronic survey via freely available software (www.
surveymonkey.com). The survey included a mix of closed
and open ended items. Four questions were answered on a
5-point Likert scale (anchored at 1 = completely disagree,
3 = neither agree nor disagree, 5 = completely agree), six
questions were multiple choice, and three questions re-
quired free text responses. The survey consisted of ques-
tions covering amount of time spent in the MDT meeting;
whether respondents thought that all cases are discussed
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spondents’ perceived usefulness of the MDT meeting;
whether cases could be treated by protocol, and which
cases this might apply to; whether cases could be priori-
tised; and whether the MDT meeting could be split into
subspeciality meetings. Questions regarding the demo-
graphics of participants were also included.
Data analyses
Descriptive statistics are reported for each element of
the evaluation (median, minimum, maximum; or per-
centage and 95% confidence intervals). Differences in
ratings of professional groups (surgeons, oncologists,
nurses) were assessed statistically using the Kruskal
Wallis test (KWT). All statistical analyses were per-
formed using SPSS version 20.0 (SPSS Inc., Chicago,
IL, USA). Significance was taken at the 0.05 level. A
qualitative approach was used to analyse responses to
free-text questions: A Grounded Theory approach was
applied using a skeleton coding framework where data
were coded to primary codes in the framework, and new
codes were added as new themes emerged in the data
[18]. Themes are presented according to frequency to
facilitate reading.
Ethics
The protocol for the study was reviewed and approved
by the Whipps Cross University Hospital Research and
Development department. Participation in the study was
on the basis of informed consent and the study was car-
ried out in compliance with the Helsinki Declaration.
Results
Characteristics of participants
In total, 173 participants completed the survey. The
overall response rate was 54% (320 email invitations
were sent). Respondents included 77 Consultant Uro-
Oncologists (44.5%), 54 Nurses (31.2%), 30 Consultant
Urologists (17.3%), and 12 other specialities (6.9%) (General
Practitioner = 3, Radiologists = 2, Radiographer = 3,
Radiotherapist = 3 and Scientist = 1).
Time spent at the urology MDT meeting
The median time per week spent at the urology MDT
meeting by Oncologists was 2.0 hours (range 0–6 hours),
by Urologists 2.0 hours (1–5 hours) and by Nurses
2.0 hours (0–5 hours) – with Oncologists also spending
significantly more time (median 2.0; range 0–6) than
Urologists or Nurses (both medians 0.0; range 0–2) in
other, non-urology MDTs (P ≤ 0.001; KWT). Sixty-eight
per cent (n = 75) of the respondents said that attending
MDT meetings saves them time later. Emergent themes
from the responses (N = 58) to the question about
how specifically the MDT meeting saves time later arepresented in Table 1 and Figure 1. Regarding the utility
of the MDT meeting, the median proportion of time
spent at the MDT meeting that respondents thought was
useful for their own patients was 60%, for their col-
leagues’ patients was 70%, and for themselves was 50%.
There were no significant differences between profes-
sional groups.
Improving the efficiency of the MDT meeting
Participants ‘agreed’ that at local (within their own hos-
pitals) or specialist (linked to regional cancer centres)
MDT meetings, some cases, for which MDT review is
currently mandatory, could be treated according to a
pre-defined pathway. There was no significant difference
between professional groups in this view (P = 0.075,
0.328; KWT). Figure 2 displays participants’ views re-
garding which cases could be treated by pre-approved
protocol, rather than being subject to full discussion in
the MDT meeting (N = 60).
The majority of respondents agreed that cases at
the MDT meeting could be prioritised by tumour
type (Yes = 80%), case complexity (Yes = 69.1%), or
the availability of MDT members within the meeting
(Yes = 61.5%).
A minority of respondents agreed that the MDT meet-
ing could be split into smaller, subspeciality meetings by
tumour type (Yes = 40%), case complexity (Yes = 16.8%),
and MDT member availability (Yes = 18.1%). There was a
significant difference between professional groups regard-
ing whether the MDT meeting could be split by MDT
member availability, with 0.0% of Urologists, 8.7% of
CNS and 32.6% of Oncologists in agreement (P = 0.001,
KWT). Data relating to participants’ free-text responses
(N = 72) to a question about the perceived disadvantages
of splitting the MDT meeting are displayed in Table 2
and Figure 3.
Discussion
Our results suggest that attending the MDT meeting is a
considerable part of our participants work load, but that
they feel that overall their attendance is useful and can
save them time later by giving them access to results,
plans, discussion with colleagues and smoothing the
pathway. Participants felt that certain cases of low risk
prostate, bladder and renal cancer could be treated by a
predefined protocol and approved at the MDT. Partici-
pants responded favourably to suggestions that cases
could be prioritised by complexity or tumour type, but
prioritisation by team members’ availability was less
popular. In contrast, participants generally did not agree
that the MDT meeting could be split into subspecial-
ity meetings neither by complexity, tumour type nor
by team members’ availability – possibly indicating a
well embedded culture of MDT working within this
Table 1 Table presenting emergent themes (Left column) from free-text responses to the question, “How does attending
the MDT meeting save time later?”
Theme Explanation
Treatment plan Plans for treatment can be formulated and clarified at MDT meeting
Investigations Investigations (e.g. radiological investigations) can be collated and reviewed
Patient consultation Being familiar with the clinical history, results of investigations and proposed treatment facilitates consultation with patients
Improving pathway The passage of patients from one clinician to another is quicker and more direct
Facilitate discussion Face to face discussion allows questions to be asked and answered directly
Referrals Inappropriate referrals can be avoided and appropriate referrals made directly in person
Record keeping A single record of results and multidisciplinary discussion can be created
Admin Patient follow-up is streamlined and patients are not lost
Non-clinical Improved relationships between team members
Explanations for the displayed themes are presented in the right column.
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as recognition of the logistical problems of having
multiple meetings.
The responses of our participants to questions about
the amount of time spent at the MDT meeting are con-
sistent with previous research carried out by the UK’s
National Cancer Action Team (NCAT) [19]. 88% of re-
spondents to the NCAT survey felt that a good MDT
can save time later, which is comparable to our result of
68%. The NCAT survey reported that respondents felt
strongly that effective MDT working resulted in im-
provements in clinical decision making, more coordi-
nated patient care and improvements to the quality of
care, findings that are consistent with the benefits in
time saving given by our respondents.Figure 1 Figure presenting emergent themes from free-text response
time later?”. Themes are presented according to frequency (N = 58).Recent evidence has emerged that the arrangement
of cases in an MDT meetings is associated with vari-
ation in the quality of decision-making [11]. Cases
closer to the start of MDT meetings are associated
with improved information presentation, improved team-
working and an increased chance of reaching a manage-
ment decision – whereas cases later in the list fare worse
in terms of the quality of their discussion. The results
of the present study suggest that members favour pri-
oritisation of cases on clinical grounds, which might
give those at the start of meetings a favourable envir-
onment for discussion. Our findings are also consist-
ent with the NCAT survey, which found that 78% of
doctors and 78% nurses felt that cases should be
grouped [5,19].s to the question, “How does attending the MDT meeting save
Figure 2 Figure displaying responses to the question, “What tumour types could be managed without going through MDT meeting
discussion?”. Data displayed according to frequency (N = 60).
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ject to certain limitations. The sample used in this study
was small, consisting only of three professional groups.
The study sample may not therefore be representative of
MDT members in general. However, participants were
recruited from national and regional forums, and as such
represent those core MDT members who have contact
with patients, from a range of locations throughout the
UK. In addition, there is a possibility that as participa-
tion was opt-in in nature, those who responded are more
favourably disposed to engaging in MDT working – this
potential for self-selection bias is present in all surveys
of this nature. Finally, the MDT members who have
participated in this study are drawn from only urology
MDTs, and therefore the results may not be generalizable
to other tumour types. However, recent evidence suggestsTable 2 Table presenting emergent themes (Left column) from
potential disadvantages of splitting the MDT meeting?”
Theme Explanation
Time restraints More time consuming to attend g
Loss of MDT approach Fragmentation of cancer care into
Unavailability of all members Difficulty scheduling multiple mee
Loss of educational value Loss of experience of broad range
Cross cover More cover needed for MDT mem
More admin work Greater amount of record keeping
Lack of communication Loss of face to face contact with s
different meeting
Explanations for the displayed themes are presented in the right column.that consensus regarding what constitutes effective MDT
working is high across common tumour types so some
of our could also be applicable to other similar (i.e.
high caseload) tumour types/teams [5]. Overall, replication
of these results with a larger sample across tumour types
other than urology will delineate the generalizability of
the findings.
Although improving the quality of decision-making
and standardising the decision-making process is a laud-
able aim, it is resource intensive and time consuming
[20]. MDT meetings in other countries (often called
tumour boards) are varied [3,9,15]. Indeed, Saini and
colleagues provide an interesting insight into the variety
of breast MDTs across 39 different countries, suggesting
that there is much variation in the structure, case mix
and decision-making processes across different countriesfree-text responses to the question, “What are the
reater number of smaller meetings
a number of different subgroups
tings into MDT members’ job plans
of tumour types
ber absence
and administrative work load associated with larger number of meetings
pecialists who may have slightly different speciality interest and attend
Figure 3 Figure presenting emergent themes from free-text responses to the question, “What are the potential disadvantages of splitting
the MDT meeting?”. Themes are presented according to frequency (N = 72).
Lamb et al. BMC Health Services Research 2014, 14:377 Page 6 of 7
http://www.biomedcentral.com/1472-6963/14/377around the world [16]. Freeman and colleagues found
that the establishment of MDT services for patients with
lung and oesophageal cnacer improved the efficacy and
efficiency of treatment [9,21]. In the UK, although cases
of recurrence, and cases without curative intent (i.e. ad-
vanced disease) do not require discussion at a Specialist
MDT meeting, these are cases that might benefit most
from a MDT approach- improving information sharing,
increasing expertise and streamlining referral between
specialities. If such cases are to be brought to MDT
meetings in the UK, then an already stretched service
might buckle under the strain. Taking simple cases away
from full MDT discussion and treating according to a
pre-approved pathway may free up time and resources
for complex cases – this is an important suggestion that
stems from this study. Such an arrangement could be
based on a combination of the clinical practice guide-
lines approved by the MDT (which may include the use
of simple decision-making tools, such as MDT-QuIC
[22]), with proposals for treatment/management circu-
lated among MDT members before being proposed in
the MDT meeting by the chair to ensure that such cases
have met minimum requirements for information and
any plans are carefully and fully recorded. A strategy
such as this could provide quality assurance (compre-
hensive process of decision-making according to clinical
practice guidelines, with the relevant information clearly
documented, possibly using MDT-QuIC as a proforma)
and quality control (decisions reviewed by the MDT, in
addition to regular audits and the national peer review
program) currently provided by full MDT discussion.The cost of MDT working has not yet been adequately
evaluated, and cost-effectiveness is even further from be-
ing defined. Estimates so far from the UK range from
£14.10 ($23.12, €16.92) to £628.53 ($1,030.79, €754.24)
per treatment plan [23]. Any assessment of the cost-
effectiveness of MDT working will have to take account
of upfront costs of MDT meetings, as well as any effi-
ciencies (in terms of time or expense) that occur later
in the treatment pathway, such as those identified by
our respondents. Strategies to improve the efficiency of
MDT meetings, either by streamlining simple cases, or
by prioritising cases on clinical grounds to use time ef-
fectively, may also help to improve cost, as well as clin-
ical effectiveness.
Conclusions
There is an increasing body of evidence that MDT work-
ing in cancer care can improve the delivery of care for
patients, as well as improving health outcomes. How-
ever, MDT working is time and resource intensive. This
study is the first to explore which areas of urology MDT
working healthcare professionals perceive to be valuable,
and how MDT working might be improved in terms of
effectiveness and efficiency. Such potential improvements
will need to be tested empirically, but may translate into
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